MedTrace Logo

ATP in Alzheimer Disease

NCT02279511 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-03-29

No results posted yet for this study

Summary

To Check whether systemic treatment with ATP alters the profile of cerebral metabolism in patients with Alzheimer's disease using MRS techniques (Magnetic Resonance Spectroscopy) and adjust the infusion (minimum effective dose) that promotes this metabolic change.

Conditions

Interventions

DRUG

ADENOSINE TRIPHOSPHATE

Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)

DRUG

PLACEBO

Infusion of 500 mL of saline solution. (IV)

Sponsors & Collaborators

  • Sara Varea

    lead OTHER

Principal Investigators

  • Mercè Boada Rovira, MD PhD · Fundació ACE. Barcelona Alzheimer Treatment and Research Center

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02279511 on ClinicalTrials.gov